CORE--MONOCLONAL ANTIBODY

$228,401P01FY2002CANIH

Dana-Farber Cancer Institute, Boston MA

Investigators

Linked publications & trials

Paper 34269527 Paper 31399473 Paper 30833638 Paper 29188306 Paper 29072302 Paper 28049147 Paper 27852846 Paper 27700986 Paper 27194756 Paper 26499495 Paper 25724416 Paper 25596282 Paper 25540383 Paper 25538195 Paper 25476789 Paper 25368431 Paper 25320321 Paper 25222147 Paper 25122798 Paper 24998850 Paper 24991009 Paper 24954536 Paper 24857551 Paper 24850740 Paper 24840522 Paper 24737887 Paper 24166507 Paper 24109229 Paper 24052256 Paper 23842645 Paper 23764425 Paper 23514892 Paper 23474680 Paper 23269662 Paper 23217616 Paper 23093934 Paper 23015706 Paper 22901813 Paper 22820256 Paper 22810586 Paper 22802530 Paper 22748924 Paper 22645313 Paper 22547818 Paper 22405651 Paper 22391450 Paper 22232672 Paper 22064854 Paper 21835797 Paper 21498570 Paper 21159657 Paper 20622853 Paper 20181716 Paper 20133580 Paper 19836046 Paper 19721090 Paper 19644473 Paper 19596781 Paper 19573809 Paper 19553310 Paper 19505649 Paper 19293187 Paper 19200708 Paper 19150725 Paper 19136134 Paper 19061646 Paper 19022468 Paper 18922873 Paper 18594509 Paper 18592025 Paper 18359290 Paper 18337582 Paper 18329957 Paper 18235218 Paper 18214640 Paper 18006659 Paper 17608567 Paper 17596310 Paper 17540176 Paper 17531812 Paper 17503741 Paper 17488820 Paper 17442716 Paper 17110335 Paper 17060635 Paper 16940503 Paper 16611886 Paper 16339315 Paper 16299534 Paper 16166293 Paper 16139224 Paper 16081543 Paper 16061792 Paper 15604246 Paper 15596855 Paper 15507652 Paper 15466190 Paper 15240878 Paper 15169897 Paper 15109495

Abstract

DESCRIPTION: (Applicant's Description) A monoclonal antibody core facility was created at the inception of this program project to produce reagents necessary for advancement of much of the research of the program. Monoclonal antibodies are fundamental to the cellular and molecular biologic approaches which the program scientists routinely use. It was recognized at the beginning of the program that these reagents were essential to the program?s success, that the commercial production of the various antibodies needed was excessively costly, that their production in individual labs posed an avoidable burden for everyone involved, and that a central facility staffed by experts and dedicated to the program could, in principle, generate the most valuable antibodies in a timely and cost-effective manner. The monoclonal antibody core has successfully produced monoclonal antibodies for every member of the program.

View original record on NIH RePORTER →